MetaboNEWS Masthead

MetaboNews
Issue 5 - December 2011

CONTENTS:



Online version of this newsletter:
http://www.metabonews.ca/Dec2011/MetaboNews_Dec2011.htm

Welcome to the fifth issue of MetaboNews, a monthly newsletter for the worldwide metabolomics community. In this month's issue, we feature a Software Spotlight article on Agilent Technologies' new GeneSpring-Mass Profiler Professional (MPP) 12.0. This newsletter is being produced by The Metabolomics Innovation Centre (TMIC, http://www.metabolomicscentre.ca/), and is intended to keep metabolomics researchers and other professionals informed about new technologies, software, databases, events, job postings, conferences, training opportunities, interviews, publications, awards, and other newsworthy items concerning metabolomics. We hope to provide enough useful content to keep you interested and informed and appreciate your feedback on how we can make this newsletter better (metabolomics.innovation@gmail.com).

Note: Our subscriber list is managed using Mailman, the GNU Mailing List Manager. To subscribe or unsubscribe, please visit https://mail.cs.ualberta.ca/mailman/listinfo/MetaboNews

Current and back issues of this newsletter can be viewed from the newsletter archive (http://www.metabonews.ca/archive.html).

Software/Stat Spotlight

1) Software Spotlight
The new Mass Profiler Professional (MPP) and GeneSpring-MPP v.12.0
Multi-omics and Pathway Analysis

Feature article contributed by Theodore Sana, Senior Scientist, Life Sciences Group, Agilent Technologies, Santa Clara, California

Agilent begins the New Year by introducing two new and improved software products for multi-omics analysis, that will be available in January 2012. The new Agilent Mass Profiler Professional 12.0 (MPP) is a powerful visualization and statistical analysis solution designed for the chemometric analysis of mass spectral data. Agilent GeneSpring-MPP 12.0 for multi-omics analysis has been designed for scientists that are interested in comparing results across different technology platforms. It combines all the capabilities of MPP with GeneSpring GX, the industry platform for gene expression analysis, as well as Next Generation Sequencing (NGS). MPP’s powerful analytical capabilities fully exploit the high information content of chromatographic/mass spectrometry (MS) data to quickly and easily discover differences between sample groups, plot changing patterns of compound abundances over time, and develop multivariate models for class prediction. An integrated ID Browser allows identification using LC/MS Personal Compound Databases such as METLIN or Forensics/Tox, and GC/MS libraries (NIST and Agilent/Fiehn library). MPP allows users to display and analyze large GC/MS or LC/MS data sets on their personal computer, regardless of whether the peaks have previously been identified or if they remain unknown.

MPP is ideally suited for applications characterized by complex sample matrices such as metabolomics, proteomics, natural products, food, beverages, flavors, fragrances, and environmental analyses. Both software platforms, however, enable the creation of single projects for single or multiple experiments analyses based on different technology types, such as transcriptomics and metabolomics: transcriptomics, proteomics, NGS, GC/MS, and LC/MS-based metabolomics. The key advantage of having access to different experiment types in the same project is the ability to perform a joint analysis, comparing results whether they originated from legacy, public, or proprietary sources. For example, it’s now possible to take a list of statistically significant results, derived from two different experiments, and project them onto curated, biological pathways through joint multi-omic pathway analysis.

What's New in GeneSpring-MPP 12.0:


Figure 1. A Profile plot of averaged Log2 normalized metabolite abundances for replicate samples across different conditions. Metabolite extracts were from cells exposed to different concentrations of antibiotics.


New Pathway Analysis and Visualization Capabilities:


Figure 2. Screen shot of the Multi-omics Analysis (MOA) wizard showing how to select two different experiments, the organism from which the data originated, and the Pathway organism onto which one wishes to map the joint analysis. The user has the choice of selecting curated pathways such as the WikiPathway collection and/or literature-derived pathways.




Figure 3. The second page of the MOA wizard allows users to independently select the interpretation (i.e., condition) and specific entity lists associated with each experiment in the joint analysis.




Figure 4. Heat map of all pathway entities, dynamically linked to pathway selection for comparative analysis. By selecting the "Arginine and Proline metabolism" pathway from the list of available WikiPathways for example, one can see the total number of metabolite entities in that pathway (82) and the number of matching entities from the experiment list (21). This applies to genes as well. In addition one can view the 21 metabolites in a heat map, with normalized abundance values color coded in a table and dynamically linked to the pathway above it.


New Visualization Enhancements:
Plus all the features you trust in GeneSpring


Figure 5. The heat map reveals two tabs; one for metabolomics results and one for genomics. By zooming in on an area of the pathway, the metabolite and genes come into focus. Citrulline, for example, has metabolite data but no data for the complementary gene "arg F".




Figure 6. Enlarged view of highlighted, blue ellipse region, indicated in Figure 5, showing the Log2 normalized abundances and their standard errors for each condition, displayed as a "Heatstrip".


Pathway Analysis in GeneSpring-MPP 12.0 allows you to interpret your experimental data through the following
features:




Figure 7. The highlighted entities in a pathway can be selected individually as a subset containing a mixture of metabolites and Entrez Gene IDs. These entities can be exported as separate lists for subsequent confirmation (for example MS/MS and PCR analysis), or for designing a new custom microarray using "e-array". This feature gives the user tremendous flexibility in hypothesizing and in designing the next experiment.


All these pathway analysis tools allow users to quickly answer questions such as:
Which probable pathways are represented by my genes or metabolites of interest?
What is the hierarchy of function of my genes or metabolites of interest?

In doing so, one can quickly determine how the experimental conditions affect certain biological pathways and processes, and not just the metabolite abundance and expression of individual genes.

Agilent Technologies' Life Sciences Group provides a team of experienced scientists who are available to work together with you to help design custom solutions to your data analysis challenges.

For more information about these software products, please contact Theodore Sana, theodore_sana@agilent.com.


 
Please note: If you know of any metabolomics research programs, software, databases, statistical methods, meetings, workshops, or training sessions that we should feature in future issues of this newsletter, please email Ian Forsythe at metabolomics.innovation@gmail.com.

Biomarker Beacon

2) Biomarker Beacon

Feature article contributed by Ian Forsythe, Editor, MetaboNews, Dept of Computing Science, University of Alberta, Edmonton, Canada

Metabolomics is an emerging field that is complementary to other omics sciences and that is gaining increasing interest across all disciplines. Because of metabolomics' unique advantages, it is now being applied in functional genomics, integrative and systems biology, pharmacogenomics, and biomarker discovery for drug development and therapy monitoring. More than 95% of today's biomarkers are small molecules or metabolites (MW <1500 Da), which can be used for disease testing, drug testing, toxic exposure testing, and food consumption tracking. While standard clinical assays are limited in the number and type of compounds that can be detected, metabolomics measures many more compounds. Since a single compound is not always the best biomarker (diagnostic, prognostic or predictive), healthcare practitioners can use metabolomics information about multiple compounds to make better medical decisions. Global metabolic profiling is now being used to determine clinical biomarkers in assessing the pathophysiological health status of patients.

In the following two recent studies, metabolomics approaches were used to develop biomarker tools for the identification of biomarkers associated with amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, respectively.

1. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2011 Nov 25. [Epub ahead of print] [PMID: 22117131]


This research team performed non-targeted metabolomics analysis to identify therapeutic targets and diagnostic biomarkers of ALS using three independent instrument platforms: 1) gas chromatography/mass spectrometry (GC/MS), 2) ultrahigh performance liquid chromatography/tandem mass spectrometry (UHLC/MS/MS2) platform optimized for basic species, and 3) UHLC/MS/MS platform optimized for acidic species. Two separate studies were carried out. Plasma samples from 62 (study 1) and 99 (study 2) ALS patients and 69 (study 1) and 48 (study 2) healthy volunteers were analyzed. In both studies, the researchers identified twenty-three metabolites that were significantly altered in plasma from ALS patients. The identified metabolites are involved in pathways associated with neuronal change, hypermetabolism, oxidative damage, and mitochondrial dysfunction, results that are consistent with proposed disease mechanisms in ALS.


2. Orešič M, Hyötyläinen T, Herukka S-K, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, Gopalacharyulu P V, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lötjönen J, Soininen H. Metabolome in progression to Alzheimer's disease. Translational Psychiatry (2011) 1, e57; doi:10.1038/tp.2011.55 [Translational Psychiatry]


In this paper, the research team sought to compare serum metabolite profiles in 47 Alzheimer's disease (AD) patients, 40 mild cognitive impairment (MCI) patients, and 46 healthy control subjects. MCI is an intermediate phase between normal aging and AD. The investigators used two analytical platforms: 1) global lipidomics platform (UPLC-MS) for the analysis of phospholipids, sphingolipids, and neutral lipids, and 2) global platform for small polar metabolites (GC x GC-TOFMS) for the analysis of amino acids, free fatty acids, keto acids, various other organic acids, sterols, and sugars. The team identified a molecular signature consisting of three metabolites that were predictive for progression to AD. The key component of the predictive model was 2,4-hydroxybutanoic acid, which was present at higher levels in patients who progressed to AD. Based on their findings, hypoxia, oxidative stress, and membrane lipid remodeling are all implicated in progression to AD. This study may aid in the development of early diagnostics and novel therapeutics for AD.

Metabolomics Current Contents

3) Metabolomics Current Contents


Recently published papers in metabolomics:
MetaboNews

4) MetaboNews
15 Dec 2011
Metabolomx test detects lung cancer from breath - Metabolomx, a diagnostic company focused on the detection of the metabolomics signature of cancer from exhaled breath, today announces publication of results from the first clinical study demonstrating a breath test that can both detect lung cancer and differentiate between types of lung cancer in humans. This seminal study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, used Metabolomx' first-generation colorimetric sensor array, and reported accuracy exceeding 80% in lung cancer detection, comparable to computerized tomography (CT) scan. Further, the study found that Metabolomx' first-generation colorimetric sensor array could identify the subtype of lung cancer (small cell versus adenocarcinoma versus squamous cell) with accuracy approaching 90%.

The availability of a low-cost, non-invasive metabolomic breath signature for lung cancer is particularly timely given the recently announced results of the National Cancer Institute's National Lung Screening Trial (NLST) calling for wider CT screening of high-risk citizens. The breath signature, which reports active tumor metabolism, is thought to provide complementary information to CT, potentially helping clinicians distinguish benign from malignant lung nodules.

The sensor detects the unique pattern of volatile organic compounds (the "metabolic biosignature") present in exhaled breath. The article, "Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer," is appearing in the current, online issue of the Journal of Thoracic Oncology (JTO), the official Journal of the International Association for the Study of Lung Cancer.

Paper: Mazzone PJ et al., Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol. 2012 Jan;7(1):137-42. [PMID: 22071780]


Source: EurekAlert!
 
14 Dec 2011
Biochemical fingerprint in the blood predicts Alzheimer's disease - A study led by Research Professor Matej Oresic from VTT suggests that Alzheimer´s disease is preceded by a molecular signature indicative of hypoxia and up-regulated pentose phosphate pathway. This indicator can be analysed as a simple biochemical assay from a serum sample months or even years before the first symptoms of the disease occur. In a healthcare setting, the application of such an assay could therefore complement the neurocognitive assessment by the medical doctor and could be applied to identify the at-risk patients in need of further comprehensive follow-up.

Alzheimer’s disease (AD) is a growing challenge to the health care systems and economies of developed countries with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing aging of populations.

The progression of Alzheimer’s disease (AD) is gradual, with the subclinical stage of illness believed to span several decades. The pre-dementia stage, also termed mild cognitive impairment (MCI), is characterised by subtle symptoms that may affect complex daily activities. MCI is considered as a transition phase between normal aging and AD. MCI confers an increased risk of developing AD, although the state is heterogeneous with several possible outcomes, including even improvement back to normal cognition.

What are the molecular changes and processes which define those MCI patients who are at high risk of developing AD? The teams led by Matej Orešič from VTT and Hilkka Soininen from the University of Eastern Finland set out to address this question, and the results were published on 13th Dec. 2011 in Translational Psychiatry.

The team used metabolomics, a high-throughput method for detecting small metabolites, to produce profiles of the serum metabolites associated with progression to AD. Serum samples were collected at baseline when the patients were diagnosed with AD, MCI, or identified as healthy controls. 52 out of 143 MCI patients progressed to AD during the follow-up period of 27 months on average. A molecular signature comprising three metabolites measured at baseline was derived which was predictive of progression to AD. Furthermore, analysis of data in the context of metabolic pathways revealed that pentose phosphate pathway was associated with progression to AD, also implicating the role of hypoxia and oxidative stress as early disease processes.

The unique study setting allowed the researchers to identify the patients diagnosed with MCI at baseline who later progressed to AD and to derive the molecular signature which can identify such patients at baseline.

Though there is no current therapy to prevent AD, early disease detection is vital both for delaying the onset of the disease through pharmacological treatment and/or lifestyle changes and for assessing the efficacy of potential AD therapeutic agents. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues.

This study was supported by the project “From patient data to personalised healthcare in Alzheimer's disease” (PredictAD) which was supported by the European Commission under the 7th Framework Programme.

Paper: M. Orešič, T. Hyötyläinen, S. -K. Currant, Sysi-Aho, M., I. Mattila, T. Seppänen-Laakso, V. Julkunen, PV Gopalacharyulu, M. Hallikainen, J. Koikkalainen, M. Stone Field, S. Heli Salmi, J. Lötjönen, H. Soininen, Thurs metabolome in the progression of Alzheimer's disease, Translational Psychiatry (2011) 1, E57; doi: 10.1038/tp.2011.55. http://www.nature.com/tp/journal/v1/n12/full/tp201155a.html


 
8 Dec 2011
Metabolon Study Reveals Mechanisms of High Dosage Pentamethyl-6-Chromanol (PMCol) Toxicity in Liver Damage and Dysfunction - Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today the publication of "Toxicogenomics and Metabolomics of Pentamethylchromanol (PMCol)-Induced Hepatotoxicity" in the journal Toxicological Sciences. The study was conducted by the Biosciences Division of SRI International in conjunction with Metabolon scientists.

The study integrated classical toxicology, toxicogenomics, and metabolomic approaches to determine the mechanism of toxicity and identify sensitive early markers of target organ injury by PMCol.

Metabolomic evaluation of the liver and plasma samples found dose- and time-dependent effects, including depletion of total glutathione and glutathione conjugates, decreased methionine and cofactors FAD and NAD(P)+, and increased S-adenosylhomocysteine, cysteine, and cystine. Chronic exposure to high doses of PMCol induced liver damage and dysfunction that is likely due to two factors: the direct inhibition of glutathione synthesis and the modification of drug metabolism pathways.

Paper: Parman T et al., Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. Toxicol Sci. 2011 Dec;124(2):487-501. Epub 2011 Sep 13. [PMID: 21920950]


Source: MarketWatch

Please note: If you know of any metabolomics news that we should feature in future issues of this newsletter, please email Ian Forsythe (metabolomics.innovation@gmail.com).

Metabolomics Events

5) Metabolomics Events
1 Feb 2012

Recent Advances and Future Directions in Applied Metabolomics
Venue: University of Manchester Centre of Excellence in Biopharmaceuticals, Manchester, UK

Join Agilent Technologies and the University of Manchester for an interesting and informative workshop on Applied Metabolomics.
  • International experts will present their work in various areas of Applied Metabolomics
  • The agenda will centre around the use of instrumentation, software and workflows to address current Metabolomics challenges
  • The day will allow for stimulating discussions and participant interaction

Speakers include:

  • Dr. Coral Barbas, CEMBIO, Madrid, Spain
  • Prof. Alan Dickson, COEBP, University of Manchester
  • Dr. Benedikt Kessler, University of Oxford
  • Dr. David Knight, Faculty of Life Sciences, University of Manchester
  • Dr. Florence Raynaud, The Institute of Cancer Research, Sutton
  • Dr. Chris Sellick, Medimmune, Cambridge
  • Dr. Oscar Yanes, University Rovira i Virgili, Spain
  • Dr. Nicola Zamboni, ETH, Zurich, Switzerland


3 Feb 2012

Cancer Metabolomics: Elucidating the Biochemical Programs that Support Cancer Initiation and Progression
Venue: New York, New York, USA

Since the 1920s, it has been recognized that cancer cells exhibit metabolic features that are distinct from those of 'normal' cells. However, a comprehensive picture of cancer metabolism and its molecular underpinnings has been essentially unapproachable—that is, until very recently. With the emergence of effective analytical strategies for broad-based metabolite profiling (both targeted and untargeted), the cancer cell 'metabolome' has now come into sight. Taking advantage of LC-MS-based analytical platforms, the participating speakers will describe new knowledge of metabolic pathways that distinguish cancer cells, signaling cascades that drive cancer-selective metabolic pathways and implications for the development of novel cancer chemotherapies.

Call for Poster Abstracts
A poster session will be held and a selected number of presenters will be asked to give brief oral presentations. The deadline for abstract submission is Friday, January 27, 2012. For abstract instructions, send an email to CancerMetabolomics@nyas.org with the words "Abstract Information" in the subject line. Instructions will be forwarded automatically. For questions, please call 212.298.8618.
 
20-22 Feb 2012

International Conference and Exhibition on Metabolomics & Systems Biology
Venue: San Francisco, USA

OMICS Group invites you to attend the International Conference and Exhibition on Metabolomics & Systems Biology which is going to be held during 20-22 February 2012 San Francisco, USA.   

Metabolomics-2012 will serve as a catalyst for the advances in the study of Metabolomics & Systems Biology by connecting scientists within and across disciplines at sessions and exhibition held at the venue, creates an environment conducive to information exchange, generation of new ideas, and acceleration of applications that benefit Research in Metabolomics & Systems Biology.
 
Conference Highlights the following topics:
  • Proteomics & Genomics     
  • Transcriptomics & Metabolomics
  • Bioinformatics    
  • Gene expression Profiling
  • Immunology    
  • Microbiology & Biochemistry
  • Computational Biology    
  • Genetics and Metabolism
  • Glycomics & Lipidomics    
For more information, please visit http://omicsonline.org/metabolomics2012/.


9-10 Mar 2012

Second International Congress of Translational Research in Human Nutrition: Integrative approaches in nutrition research
Venue: Clermont-Ferrand, France
17-20 Apr 2012

analytica Conference 2012
Venue: Munich, Germany

For the classical exhibition area, the analytica Conference provides the perfect complement. It has been a decisive factor in establishing analytica as the pre-eminent meeting point for the industry.

In various symposiums, leading scientists from all over the world report on the latest developments, current trends and visions of the future. Analytic, diagnostic, biochemical and molecular biological methods and procedures are discussed here. On the last occasion, 140 well-known experts gave talks in 23 different thematic symposiums.

Main subject emphases/highlights of the analytica Conference 2010
  • Presentation of the Gerstel Award and the Bunsen-Kirchhoff Award
  • Patient-oriented laboratory diagnostics
  • Separation techniques in the life sciences
  • Doping analytics
  • Proteome research
  • Measurement and toxicology of particulate matter
  • Modern analytical methods for the chemical analysis of art objects
  • Analytical contributions to the treatment of diabetes
The 2012 event will focus on topics such as acute diagnostics and clinical metabolomics.
7-8 May 2012

LIPID MAPS Annual Meeting 2012: Lipidomics Impact on Cell Biology, Metabolomics and Translational Medicine
Venue: La Jolla, CA, USA

This is an exciting time for the emerging field of lipidomics. With the development and evolution of sophisticated mass spectrometers linked to highly efficient liquid chromatography systems, individual molecular species of lipids can now be isolated and identified, allowing us to begin to understand lipid metabolism and the treatment of lipid-based diseases (atherosclerosis and inflammatory disease as well as arthritis, cancer, diabetes and Alzheimer's disease). Recent awareness that each category of lipid consists of thousands if not tens of thousands of individual molecular species requires sophisticated informatics to ensure consistent databasing and annotation of the numerous lipid molecular species and analysis of tremendous quantities of experimental data. The goal of this meeting is to bring together biological and biomedical scientists in a wide range of fields to share new findings and methods in the broader lipidomics field and to explore joint efforts to extend the use of these powerful new methods to new applications. Presentations will provide an excellent introduction for scientists new to these methods, and are sure to be of interest to lipidomics veterans to learn about latest techniques and research results.
 
The meeting program tentatively features the following six sessions:
  • Cancer
  • Inflammation
  • Macrophage Biology
  • Metabolic Disease
  • Metabolomics
  • Translational Medicine
For more information, please visit http://www.lipidmaps.org/meetings/2012annual/
20-24 May 2012

60th ASMS Conference on Mass Spectrometry and Allied Topics
Venue: Vancouver, BC, Canada

The conference and short courses will be held at the Vancouver Convention Centre, 1055 Canada Place, Vancouver, BC V6C 0C3, Canada.  All oral sessions, poster sessions, exhibit booths, and corporate hospitality suites will be located in the Convention Centre.

Important Dates:
Jan 9, 2012:  Conference registration and lodging opens online
Feb 3, 2012:  Deadline for submission of abstracts
Apr 14, 2012:  Conference program online
Apr 30, 2012:  Deadline for advance registration
21-23 May 2012

Les 6èmes Journées Scientifiques du Réseau Français de Métabolomique et Fluxomique (JS 6 RFMF)
Venue: Nantes, France

The 6th Scientific Days of the French Network of Metabolomics and Fluxome will be held in Nantes from 21 May 2012 to May 23, 2012, organized by the platform Corsaire, the platform of Metabolomics Biogenouest. Corsair includes eight technical support centers located throughout Western France (Brest, Nantes, Rennes, and Roscoff).
 
The main topics selected for JS 6 RFMF are:

  • Applications of metabolomics and fluxomics in the areas of the sea, agronomy and health.
  • Technological developments, bioinformatics, and statistical processing

For more information, please visit https://www.bordeaux.inra.fr/ifr103/reseau_metabolome/document/meetings/courrier_preinscription_6JSRFMF_final.rtf
25-28 June 2012

METABOLOMICS 2012: Breakthroughs in plant, microbial and human biology, clinical and nutritional research, and biomarker discovery
Venue: Washington Marriott Wardman Park Hotel, Washington, DC, USA

The Metabolomics Society is pleased to announce the location and dates for our next annual meeting 'METABOLOMICS 2012'. We will host a program full of practical workshops and parallel sessions covering the broad range of biological and technological metabolomics topics as well as provide rich opportunities for networking. Prominent scientists will speak on the state-of-the-art in a number of leading disciplines to kick off each session, after which, we will have a full agenda of innovative speakers with specific oral presentation opportunities provided for younger researchers. We invite you to reserve the above dates in your calendar and follow our website for further details, www.metabolomics2012.org.

Local Organisers: Dan Bearden, Rick Beger, Rima Kaddurah-Daouk, Lloyd W. Sumner, Don Robertson, Padma Maruvada and Donna Kimball.

For more information, please visit http://www.metabolomics2012.org.
10 July 2012

Merck Deep Dive: Translational Technologies for Basic and Clinical Scientists
Venue: Ocean Place Resort and Spa, Long Branch, New Jersey, USA

Join us for another in this quarterly unique series that brings together about 150 Merck subject experts and key vendors. Sponsors and Exhibitors can display products and services to a very focused set of the Merck community leaders. Select exhibitors are given an opportunity to privately present upcoming product development and get instant feedback from Merck on where they would like to see development go to meet their upcoming needs. Topic for this event: Translational Technologies for Basic and Clinical Scientists. Molecular BioMarkers (Proteomics/Genomics/Metabolomics) is a key part of this event.

Please note: If you know of any metabolomics lectures, meetings, workshops, or training sessions that we should feature in future issues of this newsletter, please email Ian Forsythe (metabolomics.innovation@gmail.com).


Metabolomics Jobs

6) Metabolomics Jobs

This is a resource for advertising positions in metabolomics. If you have a job you would like posted in this newsletter, please email Ian Forsythe (metabolomics.innovation@gmail.com). Job postings will be carried for a maximum of 4 issues (8 weeks) unless the position is filled prior to that date.

Jobs Offered

Job Title Employer Location Date Posted Source
Global Marketing Manager - LC/MS Business Agilent Technologies Santa Clara, CA, USA 28-Dec-2011
 LinkedIn Jobs
Research Associate, Mathematical Modeling - Applied Mathematics & Modeling Merck Greater Philadelphia Area, USA 16-Dec-2011
 LinkedIn Jobs
Associate Director - Bioinformatics Genentech United States
 16-Dec-2011
 LinkedIn Jobs
Postdoctoral researcher in environmental metabolomics University of Birmingham Birmingham, UK 15-Dec-2011
 Metabolomics Society Jobs
Post-doctoral position (18 months) - Cancer, Environment and Metabolomics LABERCA
 Nantes, France
 13-Dec-2011
 Réseau Français de Métabolomique et Fluxomique
Postdoctoral Research Associate in Functional Genomics Oak Ridge National Laboratory Oak Ridge, Tennessee, USA
 9-Dec-2011
 LinkedIn Jobs
Stable Isotopes Scientist Nestlé Research Center  Lausanne, Switzerland 1-Dec-2011
 Réseau Français de Métabolomique et Fluxomique
Research Engineer position in Biostatistics
with skills in OMICS techniques
 L.C.H., the French horse doping control laboratory Verrières le Buisson, France
 1-Dec-2011 Réseau Français de Métabolomique et Fluxomique
Three Assistant/Associate Professorships
in Metabolomics and Computational Biology
 University of Birmingham, UK Birmingham, UK 29-Nov-2011
 Metabolomics Society Jobs


Jobs Wanted

This section is intended for very highly qualified individuals (e.g., lab managers, professors, directors, executives with extensive experience) who are seeking employment in metabolomics. We encourage these individuals to submit their position requests to Ian Forsythe (metabolomics.innovation@gmail.com). Upon review, a limited number of job submissions will be selected for publication in the Jobs Wanted section.

Note: There are no postings at this time.

Free Subscription

To subscribe/unsubscribe, simply visit https://mail.cs.ualberta.ca/mailman/listinfo/MetaboNews. Please forward this newsletter to any interested colleagues or collaborators. Send your comments and feedback about this newsletter to metabolomics.innovation@gmail.com.

Back issues of this newsletter can be viewed from the newsletter archive (http://www.metabonews.ca/archive.html).